Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 11:48 AM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #75 of 83 |
Slide #75. Gilead Sciences, Inc. — YM BioSciences Inc.
Acquirer:
Gilead Sciences, Inc. (GILD)
Acquiree:
YM BioSciences Inc. (YMI)
Details:
Gilead Sciences, Inc. and YM BioSciences Inc. announced that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM's Board of Directors, and values YM at approximately U.S.$510 million, with YM reporting C$125.5 million in cash and cash equivalents as of September 30, 2012. Gilead plans to fund the acquisition with cash on hand. The transaction is expected to close in the first quarter of 2013.
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Gilead Sciences SEC Filing Email Alerts Service
Open the GILD Page at The Online Investor »
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Gilead Sciences SEC Filing Email Alerts Service
Open the YMI Page at The Online Investor »
|
||||||||||||||||||||||||
|
|||||||||
 Free Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
